7 Pharmaceuticals stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an “A” (“strong buy”) or “B” overall (“buy”).

Dermira Inc (DERM) gets a higher grade this week, advancing from a B last week to a A. The company also gets A’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of DERM stock.

Zogenix, Inc. (ZGNX) improves from a C to a B rating this week. Zogenix, Inc. is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. For more information, get Portfolio Grader’s complete analysis of ZGNX stock.

The rating of Juniper Pharmaceuticals, Inc. (JNP) moves up this week, rising from a B to a A. The company also gets A’s in sales growth and earnings revisions. For more information, get Portfolio Grader’s complete analysis of JNP stock.

This week, Oramed Pharmaceuticals Inc.’s (ORMP) ratings are up from a C last week to a B. Oramed Pharmaceuticals Inc. is a pharmaceutical company focused on the development of oral delivery solution. The company also gets A’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of ORMP stock.

Alcobra Ltd. (ADHD) boosts its rating from a C to a B this week. The company also gets A’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of ADHD stock.

This is a strong week for Apricus Biosciences, Inc. (APRI). The company’s rating climbs to B from the previous week’s C. Apricus Biosciences, Inc. engages in the research and development of pharmaceutical drugs and drug candidates based on its proprietary NexACT drug delivery technology. The company also gets A’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of APRI stock.

ProPhase Labs, Inc.’s (PRPH) ratings are looking better this week, moving up to a B from last week’s C. ProPhase Labs, Inc. manufactures zinc gluconate glycine lozenges and homeopathic gum. The company also gets A’s in earnings momentum. For more information, get Portfolio Grader’s complete analysis of PRPH stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.